论文部分内容阅读
出血副反应是影响宫内节育器(IUD)使用的最大弱点,本研究应用前瞻、随机对比的研究方法,以评价含药宫铜IUD对月经出血类型的影响。实验组为含消炎痛50mg宫铜IUD(含铜300mm~2),对照组为宫铜IUD(含铜300mm~2)。两种IUD的临床使用效果经生命表法统计,含药宫铜IUD与宫铜IUD使用一年续用率分别为每百妇女98.03和97.95。阴道出血情况采用月经出血模型分析,结果表明在各90天的参考时限中出血/滴血总天数、最大出血/滴血段长以及出血/滴血平均段长,含药宫铜IUD均小于宫铜IUD,差异有极显著意义(P<0.01)。研究结果提示含药宫铜IUD为一安全、高效并可减低含铜IUD对月经出血类型影响的新型活性IUD,值得临床推广应用。
Hemorrhagic side effects are the biggest weakness that affects the use of intrauterine device (IUD). In this study, a prospective, randomized, comparative study was conducted to evaluate the effect of IUD containing IUD on menstrual bleeding. Experimental group containing indomethacin 50mg Palace copper IUD (copper 300mm ~ 2), the control group of Palace copper IUD (copper 300mm ~ 2). The clinical effects of two kinds of IUDs were calculated according to the life table method. The one-year renewal rates of IUD and IUD were 98.03 and 97.95 respectively. Vaginal bleeding was analyzed using a model of menstrual bleeding and the results showed that the IUDs were less than that of the uterus in the reference time limit of 90 days, the total number of bleeding / total drips, the maximum bleeding / length of blood drop, and the average length of bleeding / Copper IUD, the difference was significant (P <0.01). The results suggest that drug-containing palace copper IUD is a safe, efficient and can reduce the impact of copper-containing IUD menstrual bleeding type of new active IUD, worthy of clinical application.